# Antimicrobial activity of the quinoline derivative HT61 against *Staphylococcus aureus* biofilms

Frapwell C.J.[1,2], Skipp P.J.[1,3,4], Howlin R.P.[1,3], Angus E.M.[5], Hu Y.[6,7], Coates A.R.M.[6,7], Allan R.N.[1,2 #], Webb J.S.[1,2,3 # *]

1. School of Biological Sciences, Faculty of Environmental & Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK
2. National Biofilms Innovation Centre, University of Southampton, Southampton, SO17 1BJ, UK
3. Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK
4. Centre for Proteomic Research, Institute for Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK
5. Biomedical Imaging Unit, Southampton General Hospital, Southampton, UK
6. Institute of Infection and Immunity, St George's, University of London, Cranmer Terrace, London, UK
7. Helperby Therapeutics Group plc, London, UK

* corresponding author, email: J.S.Webb@soton.ac.uk

# denotes equal contribution

**Short Title**

Response of *S. aureus* biofilms to HT61

**Word count**

1687 words

**Abstract (73 words)**

*Staphylococcus aureus* biofilms are a significant problem in healthcare settings, in part, owing to the presence of a non-dividing, antibiotic tolerant sub-population. Here we evaluated treatment of *S. aureus* UAMS-1 biofilms with HT61, a quinoline derivative shown to be effective against non-dividing *Staphylococcal spp*. HT61 was effective in reducing biofilm viability, associated with increased expression of cell wall stress and division proteins, confirming its potential as a treatment for *S. aureus* biofilm infections.

**Keywords**

*Staphylococcus aureus*, biofilm, HT61, proteomics, antimicrobial tolerance

Antimicrobial tolerant *Staphylococcus aureus* biofilms are commonly associated with chronic infections, particularly of the skin and soft tissue (1, 2). Biofilms are highly heterogeneous, containing cellular sub-populations that are non-dividing and/or are metabolically inactive. As a large proportion of clinically administered antimicrobials target actively dividing cells this adopted quiescent state renders these antimicrobials ineffective, thus allowing biofilm bacteria to survive therapeutic intervention and contribute to chronic disease (3). Ineffective treatment can also promote the evolution of resistance mechanisms within bacterial populations. In *S. aureus,* commonly evolved resistance mechanisms can render β-lactams such as penicillin, and glycopeptides such as vancomycin ineffective (MRSA and VRSA, respectively) (4, 5). The combination of biofilm tolerance and evolved resistance mechanisms means that the development of novel antimicrobials targeting biofilm bacteria is highly desirable.

HT61 is quinoline derivative that has demonstrated efficacy against both dividing and non-dividing planktonic cultures of *Staphylococcal spp.* (6–8). HT61 preferentially binds to anionic staphylococcal membrane components, causing structural instability within the membrane and cell depolarisation (6, 8). Given its effectiveness against non-dividing cells, HT61 represents an ideal candidate for targeting the dormant sub-populations present in *S. aureus* biofilms.

In this study, we investigated the efficacy of HT61 against established *in vitro S. aureus* biofilms. We also utilised a quantitative label-free proteomic approach to identify changes in protein expression following treatment of planktonic and biofilm cultures with sub-inhibitory and inhibitory concentrations of HT61, to further elucidate cellular processes linked to HT61's mechanism of action. Understanding its mechanism of action further could provide insight into effective treatments for biofilm-associated chronic infections.

*S. aureus* UAMS-1, a methicillin sensitive osteomyelitis isolate (9), was used in all experiments. Susceptibility of planktonic and biofilm cultures of *S. aureus* to a range of HT61 (Helperby Therapeutics) and vancomycin (Hospira Inc) concentrations (0.5 to 128 mg/L) was compared. HT61 is being developed as a topical agent and vancomycin has been used extensively as a successful topical treatment for chronic wounds and acute surgical site infections (10–12). All experiments were performed in tryptic soy broth, (TSB, Oxoid), using a starting inoculum of $10^5$ cells $ml^{-1}$, diluted from an overnight culture. All cultures were performed at 37 °C, with agitation (planktonic: 120 rpm, biofilm: 50 rpm).

Planktonic minimum inhibitory concentrations (MIC, minimum concentration to inhibit growth) were obtained using the broth microdilution method (7) and minimum bactericidal concentrations (MBC, concentration to elicit a 99.9% reduction in viability) were obtained after subsequent plating and colony forming unit (cfu) enumeration on tryptic soy agar (TSA). Biofilm MBCs were calculated as per Howlin *et al* (2015) (13). Briefly, biofilms were cultured in Nunc-coated 6 well plates, (Thermo-Fisher, UK), for 72 hours, with media replacements every 24 hours prior to antibiotic treatment. Following 72 hours, spent media was replaced with TSB containing the appropriate antibiotic dilution. Biofilms were incubated for a further 24 hours. The media was then removed, the biofilms rinsed twice with HBSS to remove non-adhered cells, and the biofilms detached and suspended in 1 ml HBSS using a cell scraper. Suspensions were serially diluted, plated onto TSA and cfus were enumerated following a final 24 hour incubation.

The planktonic MIC and MBC values for HT61 were 16 mg/L and 32 mg/L respectively in comparison to 4 mg/L for both the vancomycin MIC and MBC. Towards biofilms, HT61 presented with improved killing of *S. aureus* UAMS-1 biofilms compared to vancomycin, demonstrated by a biofilm MBC half that of vancomycin (32 mg/L compared to 64 mg/L). At the maximum concentration tested (128 mg/L), HT61 caused a further 1.3 log reduction in CFUs compared to vancomycin utilised at the same concentration (Figure 1). The mechanism of action for vancomycin necessitates active cell wall turnover (14) so it is possible that its reduced biofilm efficacy can be attributed to the presence of a dormant cell subpopulation. As HT61 was equally effective against biofilms and planktonic

cultures, this may suggest that its activity against non-dividing cells, as per references (6–8), confers an advantage against the biofilm phenotype.

The cellular response of planktonic and biofilm cultures following treatment with 0, 4 or 16 mg/L HT61 was then investigated using liquid chromatography mass spectrometry$^{Elevated\ Energy}$, (UPLC/$MS_E$). These HT61 concentrations were chosen as they were below the calculated planktonic and biofilm MBCs. Use of higher concentrations would have been highly bactericidal and led to the accumulation of dead cells and unwanted noise within the proteome datasets. Full details of the proteomic methods, including the method of protein isolation and instrument settings utilised, can be found in the supplementary methods. Briefly, planktonic cultures were grown in TSB for 12 hours at 37 °C with the appropriate HT61 concentrations. Biofilms were cultured for 72 hours as described, prior to replacement of the used media with TSB supplemented with HT61 at the same concentrations. Biofilms were then incubated for a further 12 hours before being harvested and suspended into 1 ml HBSS. Following mechanical lysis of the cells, proteins were extracted, purified and normalised to a final concentration of 0.25 μg/μL in 3% acetonitrile, 0.1 % formic acid (v/v).

Prepared samples were analysed using a Waters Synapt G2Si high definition mass spectrometer coupled to a nanoAcquity UPLC system using 4 μl of peptide extract. Processed data were searched against the Uniprot *S. aureus* MN8 reference database (accessed 25/01/2018) and further analysed using a combination of uniprot database searches (www.uniprot.org, accessed between 01/05/18 and 07/07/18) and gene ontology analysis using GeoPANTHER(15). Each data set was normalised

to the top 200 most abundant proteins (per ng) and proteins were suitable for quantitive analysis if the following inclusion criteria were met; present in all 3 biological replicates, false discovery rate (FDR) ≤ 1%, sequence coverage ≥ 5%. Differential expression was defined as an expression fold-change of ≥ 1.5 and ≤ 0.667 with $p \leq 0.05$, calculated using a one-tailed student t-test.

A total of 1,448 proteins were identified across planktonic and biofilm cultures. For HT61 treated planktonic cultures, 568 (4 mg/L) and 495 (16 mg/L) proteins met the inclusion criteria for quantitative analysis. For HT61 treated biofilm cultures, 461 (4 mg/L) and 498 (16 mg/L) proteins met the inclusion criteria (Table 1). HT61 treatment resulted in the differential expression of proteins involved in a variety of functions including cell wall biosynthesis, DNA synthesis, and metabolism. (see Tables S1 and S2). Interestingly, metabolic processes were generally decreased which may be an attempt by the cell to limit HT61 damage, similar to the proteomic response of MSSA to oxacillin (16).

Treatment of planktonic cultures with sub-MIC HT61 (4 mg/L), revealed the upregulation of MurD and MurI, two cell wall biosynthesis associated proteins required for the incorporation of D-glutamate into cell wall peptidoglycan (17) (Table 2). Increasing the concentration of HT61 from 4 mg/L to 16 mg/L led to upregulation of 93% (14/15) of proteins associated with cell wall biosynthesis, including 6 components of the mur ligase pathway (MurACDEFI, 2.63 mean fold increase), FemA-like protein and FemB, which are required for peptidoglycan crosslinking (2.53 mean fold increase) and a 2.19 fold upregulation of VraR, the regulator of the cell wall stress (CWS) stimulon, which is activated following stress to the cell envelope

(18). Proteins associated with DNA synthesis were also affected by HT61 treatment (Table 2). Sub-inhibitory treatment of planktonic cultures led to increased expression of DnaA and DnaX, indicating a general rise in DNA synthesis (mean 1.84 fold increase). Cell cycle associated proteins, FtsA and Obg were also upregulated (mean 2.35 fold increase) and four downregulated (GpsB, GroL, Tig and DivlVA domain protein, mean 0.28 fold decrease). Treatment with 16 mg/L HT61 led to the increased expression of proteins associated with DNA maintenance, including three protein with helicase activity (PcrA, GyrA and ParE).

Biofilms treated with HT61 presented with a similar, albeit more muted response (Table 1). Notably, when treated with HT61 at 16 mg/L, increased expression was observed for both MurD (1.59 fold) and PcrA (2.13 fold), similar to planktonic cultures (Table 2). It is possible that the response across both planktonic and biofilm cultures is a result of SOS response activation. The SOS response is activated upon DNA damage and due to its quinolone-like structure, it is possible that HT61 is moonlighting as a DNA gyrase inhibitor, or other SOS-response inducer, leading to a cellular response much like that induced by quinolone antimicrobials, such as ciprofloxacin (19–21).

As well as being part of the CWS stimulon, a number of the differentially expressed cell wall biosynthesis components, DNA synthesis/maintenance genes and cell cycle components comprise a segment of the division cell wall, *dcw* cluster, a family of genes that are vital for maintaining cell shape and integrity (22, 23). Previous studies have shown that HT61 preferentially binds to anionic phospholipids in the *S. aureus* cell membrane, in a manner similar to the lipopeptide antimicrobial, daptomycin (8,

24, 25). Daptomycin inserts into the cell membrane, leading to alterations in membrane curvature, potassium efflux and membrane depolarisation (24, 25), with membrane curvature shown to impair cell wall synthesis by affecting the cell wall biosynthesis protein, MurG (26). In addition, transcriptional profiling has also shown that daptomycin upregulates components of the cell wall stimulon, suggesting a secondary mechanism of action and/or interactions with the associated components (27). Altered expression of the *dcw* cluster has also been documented in biofilms of *Haemophilus influenzae* following D-methionine treatment, contributing to altered cell morphology (22). It is possible that HT61 functions in a similar manner to these examples, either by directly interfering with cell wall biosynthesis machinery or placing stress directly on the cell membrane, interfering with the cell wall machinery.

To conclude, we have demonstrated that HT61 is more effective than vancomycin at treating *in vitro* biofilms of *S. aureus*, although whether this translates to efficacy *in vivo* needs to be determined. Furthermore, the safety and tolerated dose of HT61 will need to be evaluated in order to determine whether it is a superior therapy to vancomycin in a clinical setting. We have also shown that HT61 influences the expression of the CWS stimulon, *dcw* cluster, in line with its predicted mechanism of action. Similar to other quinoline-like compounds it may also stimulate the SOS response.

## Acknowledgements

Proteomic data is available at the following: https://doi.org/10.5258/SOTON/D0619

Statistical analyses were performed using R version 3.6.0 and figures were plotted using ggplot2 and cowplot(28–30).

## Source(s) of Support

This work was funded by a Biotechnology and Biological Sciences Research Council CASE Studentship award in partnership with Helperby Therapeutics, (BB/L016877/1). Instrumentation in the Centre for Proteomic Research is supported by the BBSRC (BM/M012387/1) and the Wessex Medical Trust.

## Declarations of Interest

YH and ARMC are shareholders in Helperby Therapeutics Group plc. YH is the Director of Research and ARMC is a company founder and the Chief Scientific Officer.

## Ethical Approval

Not required.

## References


1. Thomer L, Schneewind O, Missiakas D. 2016. Pathogenesis of *Staphylococcus aureus* Bloodstream Infections. Annu Rev Pathol Mech Dis 11:343–364.
2. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. 2015. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28:603–61.
3. Stewart PS. 2015. Antimicrobial tolerance in biofilms. Microb Biofilms, 2nd Ed 3:269–285.
4. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group AO, Al-Abri SS, Jalil NA, Benzonana N, Bhattacharya S, Brink AJ, Burkert FR, Cars O, Cornaglia G, Dyar OJ, Friedrich AW, Gales AC, Gandra S, Giske CG, Goff DA, Goossens H, Gottlieb T, Blanco MG, Hryniewicz W, Kattula D, Jinks T, Kanj SS, Kerr L, Kieny M-P, Kim YS, Kozlov RS, Labarca J, Laxminarayan R, Leder K, Leibovici L, Levy-Hara G, Littman J, Malhotra-Kumar S, Manchanda V, Moja L, Ndoye B, Pan A, Paterson DL, Paul M, Qiu H, Ramon-Pardo P, Rodríguez-Baño J, Sanguinetti M, Sengupta S, Sharland M, Si-Mehand M, Silver LL, Song W, Steinbakk M, Thomsen J, Thwaites GE, Meer JW van der, Kinh N Van, Vega S, Villegas MV, Wechsler-Fördös A, Wertheim HFL, Wesangula E, Woodford N, Yilmaz FO, Zorzet A. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318–327.

5. Wistrand-Yuen E, Knopp M, Hjort K, Koskiniemi S, Berg OG, Andersson DI. 2017. Evolution of high-level resistance during low-level antibiotic exposure. Nat Commun.

6. Hu Y, Shamaei-Tousi A, Liu Y, Coates A. 2010. A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: A novel topical antibiotic for Staphylococcal infections. PLoS One 5:e11818.

7. Hu Y, Coates ARM. 2013. Enhancement by novel anti-methicillin-resistant *Staphylococcus aureus* compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: *in vitro* and *in vivo* studies. J Antimicrob Chemother 68:374–384.

8. Hubbard ATM, Barker R, Rehal R, Vandera K-KA, Harvey RD, Coates ARM. 2017. Mechanism of action of a membrane-active quinoline-based antimicrobial on natural and model bacterial membranes. Biochemistry 56:1163–1174.

9. Gillaspy AF, Hickmon SG, Skinner RA, Thomas JR, Nelson CL, Smeltzer MS. 1995. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect Immun 63:3373–80.

10. Albaugh KW, Biely SA, Cavorsi JP. 2013. The effect of a cellulose dressing and topical vancomycin on Methicillin-resistant Staphylococcus Aureus (MRSA) and gram-positive organisms in chronic wounds: A case Series. Ostomy Wound Manag.

11. Saif A Bin, Jabbar S, Akhtar MS, Mushtaq A, Tariq M. 2019. Effects of topical Vancomycin Dressing on Methicillin-Resistant Staphylococcus Aureus (MRSA) positive diabetic foot ulcers. Pakistan J Med Sci 35:1099–1103.

12. Mallela AN, Abdullah KG, Brandon C, Richardson AG, Lucas TH. 2017.

Topical Vancomycin Reduces Surgical-Site Infections After Craniotomy: A Prospective, Controlled Study. Neurosurgery 83:761–767.

13. Howlin RP, Brayford MJ, Webb JS, Cooper JJ, Aiken SS, Stoodley P. 2015. Antibiotic-loaded synthetic calcium sulfate beads for prevention of bacterial colonization and biofilm formation in periprosthetic infections. Antimicrob Agents Chemother 59:111–120.

14. Belley A, Lalonde Seguin D, Arhin F, Moeck G. 2016. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State. Antimicrob Agents Chemother 60:4342–5.

15. Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, Thomas PD. 2017. PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res 45:D183–D189.

16. Liu X, Hu Y, Pai P-J, Chen D, Lam H. 2014. Label-free quantitative proteomics analysis of antibiotic response in *Staphylococcus aureus* to oxacillin. J Proteome Res 13:1223–1233.

17. Barreteau H, Kovač A, Boniface A, Sova M, Gobec S, Blanot D. 2008. Cytoplasmic steps of peptidoglycan biosynthesis. FEMS Microbiol Rev 32:168–207.

18. Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ. 2003. Genome-wide transcriptional profiling of the response of *Staphylococcus aureus* to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology 149:2719–2732.

19. Conley ZC, Bodine TJ, Chou A, Zechiedrich L. 2018. Wicked: The untold story

of ciprofloxacin. PLOS Pathog 14:e1006805.

20. Jara LM, Cortés P, Bou G, Barbé J, Aranda J. 2015. Differential roles of antimicrobials in the acquisition of drug resistance through activation of the SOS response in Acinetobacter baumannii. Antimicrob Agents Chemother 59:4318–4320.

21. Torres-Barceló C, Kojadinovic M, Moxon R, MacLean RC. 2015. The SOS response increases bacterial fitness, but not evolvability, under a sublethal dose of antibiotic. Proc R Soc B Biol Sci 282:20150885.

22. Dawe H, Berger E, Sihlbom C, Angus EM, Howlin RP, Laver JR, Tebruegge M, Hall-Stoodley L, Stoodley P, Faust SN, Allan RN. 2017. D-methionine interferes with non-typeable *Haemophilus influenzae* peptidoglycan synthesis during growth and biofilm formation. Microbiology 163:1093–1104.

23. Tamames J, González-Moreno M, Mingorance J, Valencia A, Vicente M. 2001. Bringing gene order into bacterial shape. Trends Genet 17:124–126.

24. Straus SK, Hancock REW. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta - Biomembr 1758:1215–1223.

25. Steenbergen JN, Alder J, Thorne GM, Tally FP. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283–288.

26. Müller A, Wenzel M, Strahl H, Grein F, Saaki TN V., Kohl B, Siersma T, Bandow JE, Sahl H-G, Schneider T, Hamoen LW. 2016. Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains. Proc Natl Acad Sci.

27. Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ. 2008. Transcriptional profiling reveals that daptomycin induces the *Staphylococcus aureus* cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother 52:980–90.

28. R Core Team 2019. 2019. R: A language and environment for statistical computing. R Found Stat Comput Vienna, Austria URL http//wwwR-project.org/.

29. Wickham H. 2016. ggplot2 Elegant Graphics for Data AnalysisJournal of the Royal Statistical Society: Series A (Statistics in Society).

30. Wilke CO. 2015. Cowplot: streamlined plot theme and plot annotations for ggplot2. R Packag version 050 Available https//cran.rproject.org/web/packages/cowplot/index.html.

**Table 1:** Summary of differential protein expression between untreated, sub-MIC (4 mg/L), and MIC (16 mg/L) treated *S. aureus* planktonic and biofilm cultures. Inclusion criteria for quantitative analysis and comparison was set at 3 peptide matches, false discovery rate (FDR) ≤ 1%, sequence coverage ≥ 5%, with $p \leq 0.05$.

| Planktonic | | | | |
|---|---|---|---|---|
| **HT61 Concentration** | **Unchanged** | **Up Regulated** | **Down Regulated** | **Total** |
| **4 mg/L** | **540** (88.7%) | **39** (6.9%) | **25** (4.4%) | 568 |
| **16 mg/L** | **270** (54.5%) | **103** (20.8%) | **122** (24.6%) | 495 |

| Biofilm | | | | |
|---|---|---|---|---|
| **HT61 Concentration** | **Unchanged** | **Up** | **Down** | **Total** |
| **4 mg/L** | **436** (94.6%) | **3** (0.7%) | **20** (4.3%) | 461 |
| **16 mg/L** | **472** (94.8%) | **9** (1.8%) | **17** (3.4%) | 498 |

**Table 2:** Differentially expressed proteins associated with the *dcw* and cell wall stimulon in *S. aureus* following treatment of planktonic cultures with HT61. Expression ratios reflect changes in expression between untreated cultures and those treated with either sub-MIC (4 mg/L) or MIC (16 mg/L) concentrations of HT61. Differential expression in biofilms indicated in brackets. Differential expression is defined as a fold change ≥ 1.5 for upregulation (green cells) and ≤ 0.667 for down regulation (red cells). Grey cells indicate no change in expression. Empty cells – proteins not identified.

| | | | | Expression Ratio | |
|---|---|---|---|---|---|
| | **Accession Number** | **Protein Name** | **Gene** | **Sub-MIC** | **MIC** |
| **Cell Cycle** | A0A0E1X830_STAAU | Cell division protein FtsA | *ftsA* | 1.38 | 1.66 |
| | A0A0E1X718_STAAU | GTPase Obg | *cgtA* | 1.30 | 3.04 |
| | A0A0E1X5J2_STAAU | Cell cycle protein GpsB | *gpsB* | 1.10 | 0.20 |
| | A0A0E1XAY0_STAAU | 60 kDa chaperonin | *groL* | 1.13 | 0.29 |
| | A0A0E1XGT1_STAAU | DivIVA domain protein | HMPREF0769_12587 | 1.05 | 0.29 |
| | A0A0E1X4P6_STAAU | Trigger factor | *tig* | 1.01 | 0.34 |
| **Cell Wall Biosynthesis** | A0A0E1XHI9_STAAU | DltD central region | *dltd* | 1.78 | 2.51 |
| | A0A0E1X5R6_STAAU | FemAB family protein (FemA) | HMPREF0769_12373 (*femA*) | 1.05 | 1.82 |
| | A0A0E1XIT0_STAAU | UDP-N-acetylglucosamine 1-carboxyvinyltransferase | *murA1* | 0.98 | 2.05 |
| | A0A0E1XAN0_STAAU | UDP-N-acetylglucosamine 1-carboxyvinyltransferase | *murA2* | 1.12 | 2.83 |
| | A0A0E1X4D8_STAAU | UDP-N-acetylmuramate--L-alanine ligase | *murC* | | 2.40 |
| | A0A0E1X8P8_STAAU | UDP-N-acetylmuramoylalanine--D-glutamate ligase | *murD* | 1.84 | 3.43 (1.59 Biofilm) |
| | A0A0E1X6V3_STAAU | UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--L-lysine ligase | *murE* | 1.05 | 1.76 |
| | A0A0E1XIV1_STAAU | UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase | *murF* | 1.33 | 2.31 |
| | A0A0E1X8U4_STAAU | Glutamate racemase | *murI* | 1.52 | 3.62 |
| | A0A0E1XKB3_STAAU | Ribulose-5-phosphate reductase | *tarJ* | 1.12 | 2.58 |
| | A0A0E1XJG3_STAAU | Response regulator protein VraR | *vraR* | | 2.19 |
| | A0A0E1X974_STAAU | Mur ligase middle domain protein | HMPREF0769_11280 | 1.32 | 2.67 |
| | A0A0E1X785_STAAU | D-alanine--D-alanyl carrier protein ligase | *dltA* | 1.15 | 1.92 |

| | | | | | |
|---|---|---|---|---|---|
| | A0A0E1XG48_STAAU | Aminoacyltransferase FemB | *femB* | 0.99 | 3.24 |
| | A0A0E1X6S7_STAAU | Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase | HMPREF0769_12730 | 0.89 | 0.63 |
| **DNA Maintenance/Synthesis** | A0A0E1XAS7_STAAU | ATP-dependent DNA helicase | *pcrA* | 1.31 | 3.07 (2.13 Biofilm) |
| | A0A0E1X928_STAAU | DNA ligase | *ligA* | 1.29 | 1.73 |
| | A0A0E1XAK8_STAAU | Chromosomal replication initiator protein DnaA | *dnaA* | 2.07 | 2.90 |
| | A0A0E1XB29_STAAU | DNA polymerase III subunit gamma/tau | *dnaX* | 1.60 | 2.07 |
| | A0A0E1X6I5_STAAU | DNA polymerase I | *polA* | 1.37 | 1.51 |
| | A0A0E1XAK2_STAAU | DNA gyrase subunit A | *gyrA* | 1.12 | 1.55 |
| | A0A0E1X7H6_STAAU | DNA topoisomerase 4 subunit B | *parE* | 1.30 | 3.34 |
| | A0A0E1XFV3_STAAU | DNA-binding protein HU | *hup* | 0.91 | 0.33 |
| | A0A0E1X9G8_STAAU | Nucleoid-associated protein HMPREF0769_10004 | HMPREF0769_10004 | | 0.15 |

Antimicrobial Agents and Chemotherapy




**Figure 1:** Log Reduction in *S. aureus* UAMS-1 viable counts of an established 72 hour biofilm following treatment with HT61 and vancomycin. HT61 consistently elicited a greater log reduction in CFU counts than vancomycin, demonstrating its potential as an antibiofilm agent. A higher value indicates a greater log reduction in CFUs. n = 3. Error bars indicate standard deviation. Statistical analyses were performed using R version 3.6.0 and figures were plotted using ggplot2 and cowplot [25–27]